Jennifer Jordan

Director, Key Accounts- Oncology Market Access at Stemline Therapeutics

Jennifer Jordan has a diverse work experience in the pharmaceutical and healthcare industries. Jennifer is currently working as the Director, Key Accounts- Oncology Market Access at Stemline Therapeutics since January 2023. Prior to that, Jennifer worked at The Janssen Pharmaceutical Companies of Johnson & Johnson for several years. Jennifer'sroles at Janssen included being a Key Account Manager in the Oncology department from August 2020 to January 2023, a Key Account Manager from September 2019 to January 2020, and an Executive Sales Specialist from April 2017 to September 2019. Before joining Janssen, Jennifer worked at Johnson & Johnson as an Access Services Sr. Manager from May 2014 to April 2017, and as a Key Stakeholder Manager Oncology from January 2013 to April 2014. Jennifer also held the position of Sr Oncology Specialist at Janssen, Pharmaceutical Companies of Johnson and Johnson from January 2011 to December 2012. Jennifer's earlier work experience includes being an Account Manager at Marcaria.com from July 2009 to December 2010, and a Hematology Sales Representative at Novartis from April 2007 to April 2009. Jennifer started their career at and gained sales experience at The Janssen Pharmaceutical Companies of Johnson & Johnson, where they held the positions of Institutional Product Specialist from June 2005 to June 2007, and Product Specialist from May 2003 to June 2005.

Jennifer Jordan attended the University of Arizona from 1999 to 2003. The degree and field of study are not provided. In 2000 to 2001, they participated in a Study Abroad Program at Universidad LCI Veritas, focusing on Spanish. Jennifer also has additional certifications, including a Population Health Policy Course from Thomas Jefferson University and a Rutgers Health Policy Immersion Course, though the details of when and where they obtained these certifications are not provided.

Links

Previous companies

Novartis logo

Timeline

  • Director, Key Accounts- Oncology Market Access

    January, 2023 - present